MedPath
Found 1 clinical trials|View Analysis
Sort by:

Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk

Phase 2
Recruiting
Conditions
Breast Cancer
Interventions
Drug: Anti-aromatase inhibitor
First Posted Date
2022-03-28
Last Posted Date
2024-02-05
Lead Sponsor
UNICANCER
Target Recruit Count
696
Registration Number
NCT05297617
Locations
🇫🇷

Centre Hospitalier Universitaire de Limoges, Limoges, France

🇫🇷

Institute Gustave Roussy, Villejuif, France

© Copyright 2025. All Rights Reserved by MedPath